Lansen Pharmaceutical Holdings Past Earnings Performance
Past criteria checks 3/6
Lansen Pharmaceutical Holdings's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 1.5% per year. Lansen Pharmaceutical Holdings's return on equity is 6%, and it has net margins of 11.4%.
Key information
-6.2%
Earnings growth rate
-6.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 1.5% |
| Return on equity | 6.0% |
| Net Margin | 11.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18
Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Sep 04We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings
Dec 28
Revenue & Expenses Breakdown
How Lansen Pharmaceutical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 65 | 7 | 29 | 2 |
| 31 Mar 23 | 65 | 8 | 29 | 2 |
| 31 Dec 22 | 66 | 9 | 29 | 2 |
| 30 Sep 22 | 64 | 7 | 28 | 2 |
| 30 Jun 22 | 63 | 6 | 27 | 4 |
| 31 Mar 22 | 58 | 4 | 27 | 3 |
| 31 Dec 21 | 54 | 1 | 27 | 3 |
| 30 Sep 21 | 53 | -3 | 27 | 1 |
| 30 Jun 21 | 51 | -7 | 28 | 0 |
| 31 Mar 21 | 53 | 41 | 27 | 0 |
| 31 Dec 20 | 54 | 88 | 27 | 0 |
| 30 Sep 20 | 55 | 99 | 28 | 0 |
| 30 Jun 20 | 55 | 110 | 29 | 0 |
| 31 Mar 20 | 55 | 64 | 31 | 0 |
| 31 Dec 19 | 54 | 18 | 33 | 0 |
| 30 Sep 19 | 51 | 6 | 34 | 0 |
| 30 Jun 19 | 47 | -6 | 35 | 0 |
| 31 Mar 19 | 52 | -3 | 34 | 0 |
| 31 Dec 18 | 57 | 0 | 33 | 0 |
| 30 Sep 18 | 66 | 2 | 35 | 0 |
| 30 Jun 18 | 75 | 4 | 37 | 0 |
| 31 Mar 18 | 82 | 10 | 41 | 0 |
| 31 Dec 17 | 89 | 16 | 44 | 0 |
| 30 Sep 17 | 93 | 18 | 44 | 0 |
| 30 Jun 17 | 96 | 21 | 44 | 0 |
| 31 Mar 17 | 95 | 12 | 44 | 0 |
| 31 Dec 16 | 95 | 4 | 45 | 0 |
| 30 Sep 16 | 95 | 3 | 43 | 0 |
| 30 Jun 16 | 94 | 1 | 42 | 0 |
| 31 Mar 16 | 94 | 2 | 41 | 0 |
| 31 Dec 15 | 93 | 2 | 39 | 0 |
| 30 Sep 15 | 101 | 7 | 41 | 0 |
| 30 Jun 15 | 110 | 13 | 43 | 0 |
| 31 Mar 15 | 113 | 13 | 45 | 0 |
| 31 Dec 14 | 117 | 14 | 46 | 0 |
| 30 Sep 14 | 110 | 13 | 44 | 0 |
| 30 Jun 14 | 104 | 13 | 43 | 0 |
| 31 Mar 14 | 100 | 12 | 41 | 0 |
| 31 Dec 13 | 95 | 12 | 40 | 0 |
| 30 Sep 13 | 97 | 13 | 41 | 0 |
| 30 Jun 13 | 99 | 14 | 43 | 0 |
| 31 Mar 13 | 96 | 14 | 42 | 0 |
| 31 Dec 12 | 94 | 14 | 41 | 0 |
Quality Earnings: 503 has high quality earnings.
Growing Profit Margin: 503's current net profit margins (11.4%) are higher than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 503's earnings have declined by 6.2% per year over the past 5 years.
Accelerating Growth: 503's earnings growth over the past year (20.1%) exceeds its 5-year average (-6.2% per year).
Earnings vs Industry: 503 earnings growth over the past year (20.1%) did not outperform the Pharmaceuticals industry 24%.
Return on Equity
High ROE: 503's Return on Equity (6%) is considered low.